Laninamivir as good as Tamiflu in Asian Phase III trial
This article was originally published in Scrip
Executive Summary
Top line results from a Phase III comparative study have shown Daiichi Sankyo/Biota Holdings' inhaled long-acting neuraminidase inhibitor laninamivir (CS-8958) was non-inferior to Tamiflu in terms of time to resolution of flu symptoms in adult and paediatric patients.